Therefore, additional research on a larger number of subjects is needed to elucidate whether the presence of JAK2 mutation per se may indeed be associated with an increased risk of developing sOA in MPN and in the general population as well (i.e., as a biomarker of clonal hematopoiesis of indeterminate potential–CHIP). The gene discussed is JAK2; the disease is myeloproliferative disorder.